Best Agrolife Q1 FY27 Earnings Call — Analysis (NSE: BESTAGRO)
Best Agrolife doubles PAT to ₹41 Cr in Q1FY27 on gross margin surge to 37%, driven by patent mix shift, while revenue growth remains muted at 4%.
The take
Q1FY27 Revenue from operations ₹396 Cr ( +4% YoY ) . New guidance — FY27 patented portfolio share of bra… 60-70% . New story: Shift to patented product portfolio .
Results
Revenue ₹396 Cr (+4% YoY); EBITDA ₹78 Cr (+70% YoY), margin 20% (vs 12%); PAT ₹41 Cr (+104% YoY); gross margin 37% (vs 29%).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from operations | ₹396 Cr | +4% | yoy · Q1FY27 |
| Gross profit | ₹146 Cr | +32% | yoy · Q1FY27 |
| Gross margin | 37% | +800bps | yoy · Q1FY27 · vs 29% |
| EBITDA | ₹78 Cr | +70% | yoy · Q1FY27 |
| EBITDA margin | 20% | +800bps | yoy · Q1FY27 · vs 12% |
| PAT | ₹41 Cr | +104% | yoy · Q1FY27 |
| PAT margin | 10% | +500bps | yoy · Q1FY27 · vs 5% |
| Branded sales volume growth | 13% | +13% | yoy · Q1FY27 |
| Patented volume growth | 37% | +37% | yoy · Q1FY27 |
| Patented share of branded sales | 64% | +1900bps | yoy · Q1FY27 · vs 45% |
| Inventory | ₹764 Cr | -6% | yoy · Jun-26 · vs ₹812 Cr as of Jun-25 |
Guidance
Management guided to 10-15% annual revenue growth and sustainable EBITDA margins of 13-14%, with patented products targeted at 60-70% of branded sales; capex plans remain on hold.
What management committed to
- In FY27, the company's patented products will account for 60-70% of branded sales. — 60-70%, FY27
- Sustainable EBITDA margins will be 13-14% in normal years. — 13-14%, in normal years
- The company's revenue CAGR over the medium term will be 10-15%. — 10-15%, medium term / each year
- Expected sales returns from Q1FY27 billings are approximately ₹60 Cr (20% of Q1 sales). — ₹60 Cr (20%), FY27
Key themes
Patented portfolio expansion and margin recovery
How the narrative shifted
- Monsoon uncertainty and demand recovery: Management frames delayed monsoons as a transient headwind and is cautiously optimistic about improving rainfall driving Q2 demand.
- Shift to patented product portfolio: The deliberate pruning of generics and expansion of patented offerings is the primary driver of margin expansion and farmer loyalty.
- Profitability over volume growth: Management is prioritizing margin quality and bottom-line resilience, even at the cost of slower top-line growth, signalling a more mature earnings profile.
- Disciplined inventory and working capital management: A 6% YoY reduction in inventory and pre-emptive provisioning for sales returns reflect a focus on capital efficiency and risk mitigation.
- Capex pause and resetting growth ambition: The decision to hold capex and lower the growth target from ~20% to 10-15% is framed as a stabilization measure after two difficult years, with a promise to return to expansion once confidence is restored.
- International registration pipeline: Product registrations in Nepal, Thailand, Vietnam, Mexico, and fast-tracked approvals in Sri Lanka are presented as future growth levers that will add geographic diversification.
Operational commentary
- Patented portfolio share surged to 64% of branded sales (from 45% YoY), driven by pruning low-margin generics and launching three new patented products; patented volumes rose 37% YoY.
- Gross margin expanded to 37% (from 29%) reflecting favourable product mix, selective price increases, and procurement/manufacturing efficiencies; EBITDA margin reached 20%.
- Successfully passed on raw material cost increases from the US-Iran conflict through two rounds of price hikes in April and May, with selective higher increases on patented products, protecting margins.
- Working capital improved: inventory reduced 6% YoY to ₹764 Cr; focus remains on inventory optimization and efficient capital utilisation.
- International registrations secured in Nepal, Thailand, Vietnam, and Mexico; fast-track approval for patented products in Sri Lanka provides a pipeline for exports.
- New product launches (Fluzam, Cubax PowerExtra, PGR portfolio) are progressing well; PGR demand expected to improve from Q2 as crops enter vegetative phase.
- Capex plans remain on hold; organic growth ambition scaled back to 10-15% CAGR, with QIP discussions ongoing but no commitment.
Analyst Q&A
Q. Could you elaborate on what has worked for gross margin improvement and how sustainable are these margins?
CFO Vikas Jain explained the margin lift came from discontinuing low-margin generics and launching three new patented products, raising patented contribution to 64% of branded sales. Margin sustainability will be maintained as generic share remains low and new patents are added.
Q. Can you quantify your current market share in branded crop protection and your expectations for next year?
Management did not provide a specific market share figure, describing the market as dynamic and stating that the company focuses on countering pest resistance with specialized molecules. The overall industry growth is 4-6%, and the company aims to outperform through its differentiated portfolio.
Q. Are you sure you are not concluding high-margin branded products to distributors in Q1 to show good numbers and will take a hit in Q3/Q4 like the last three years?
Vikas Jain stated that patented product sales continue in Q2 due to delayed season, and the company has created a sales return provision of ₹60 Cr (20% of sales) to cushion volatility in Q3/Q4, reflecting a more conservative approach.
Research and educational content only. Not investment advice.